Glyciphage-VG2 Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. Each sustained-release tablet contains Glimepiride 2 mg, Metformin 500 mg, and Voglibose 0.2 mg, targeting multiple pathophysiological defects associated with hyperglycemia. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, mitigating postprandial hyperglycemia. The sustained-release formulation ensures gradual drug release, promoting better patient adherence and minimizing gastrointestinal side effects commonly associated with metformin and voglibose. Glyciphage-VG2 is indicated as adjunctive therapy to diet and exercise for patients inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with renal or hepatic impairment, and periodic monitoring of blood glucose and renal function is recommended. This combination therapy should be used under medical supervision, with attention to potential hypoglycemia, gastrointestinal disturbances, and contraindications such as diabetic ketoacidosis or severe infections. Glyciphage-VG2 offers a comprehensive approach to managing type 2 diabetes by addressing fasting and postprandial glucose levels effectively.